Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
2.570
0.00 (0.00%)
Jan 23, 2026, 9:30 AM EST - Market open
Biomerica Revenue
Biomerica had revenue of $1.21M in the quarter ending November 30, 2025, a decrease of -26.04%. This brings the company's revenue in the last twelve months to $4.46M, down -20.05% year-over-year. In the fiscal year ending May 31, 2025, Biomerica had annual revenue of $5.31M, down -1.92%.
Revenue (ttm)
$4.46M
Revenue Growth
-20.05%
P/S Ratio
1.51
Revenue / Employee
$82,537
Employees
54
Market Cap
7.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 5.31M | -104.00K | -1.92% |
| May 31, 2024 | 5.42M | 76.00K | 1.42% |
| May 31, 2023 | 5.34M | -13.53M | -71.71% |
| May 31, 2022 | 18.87M | 11.67M | 162.13% |
| May 31, 2021 | 7.20M | 506.32K | 7.57% |
| May 31, 2020 | 6.69M | 1.49M | 28.69% |
| May 31, 2019 | 5.20M | -363.50K | -6.53% |
| May 31, 2018 | 5.56M | -227.49K | -3.93% |
| May 31, 2017 | 5.79M | 651.85K | 12.68% |
| May 31, 2016 | 5.14M | 177.44K | 3.58% |
| May 31, 2015 | 4.96M | -158.08K | -3.09% |
| May 31, 2014 | 5.12M | -1.35M | -20.89% |
| May 31, 2013 | 6.47M | 391.83K | 6.44% |
| May 31, 2012 | 6.08M | 1.18M | 24.12% |
| May 31, 2011 | 4.90M | -175.85K | -3.46% |
| May 31, 2010 | 5.08M | 140.45K | 2.85% |
| May 31, 2009 | 4.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Venus Concept | 58.88M |
| Trinity Biotech | 48.57M |
| STRATA Skin Sciences | 30.98M |
| INVO Fertility | 6.94M |
| Tenon Medical | 3.23M |
| Movano | 500.00K |
| Nexalin Technology | 156.93K |
| Profusa | 75.00K |
BMRA News
- 8 days ago - Biomerica Reports Second Quarter Fiscal 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test - GlobeNewsWire
- 6 weeks ago - Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio - GlobeNewsWire
- 2 months ago - Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - GlobeNewsWire
- 2 months ago - Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand - GlobeNewsWire
- 3 months ago - Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S. - GlobeNewsWire
- 3 months ago - Biomerica Reports First Quarter Fiscal 2026 Financial Results - GlobeNewsWire
- 3 months ago - Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors - GlobeNewsWire